A return of over 9x in just three years. That's the sizzling trajectory for Revolution Medicines (NASDAQ: RVMD). It's one of the hottest biotech stocks of 2026, with shares soaring more than 130%. Revolution Medicines' performance is the direct result of buzz about its cancer therapy Rasonque (daraxonrasib). The U.S. Food and Drug Administration (FDA) approved the drug for the treatment of pancreatic cancer in August 2026. There's no question that investors who jumped aboard the Revolution Medicines train early have made a lot of money so far. But could Revolution Medicines be a millionaire-maker stock going forward?
CryptoAlerta — análise de criptomoedas e mercado em tempo real